Blood test distinguishes neuroendocrine subtype of advanced prostate cancer

Like a criminal entering a witness protection program, cancer cells can shed their past and take on a new identity. Detecting such an identity switch is particularly challenging when metastatic castration-resistant prostate cancer (CRPC) advances from adenocarcinoma to neuroendocrine prostate cancer (NEPC), a very difficult cancer to treat.

Leave A Comment

Your email address will not be published. Required fields are marked *